P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

• N. Harbeck,
• J.-F. Boileau,
• S. Modi,
• C. Kelly,
• S. Ohno,
• J. Wu,
• A. Konpa,
• P. Herbolsheimer,
• S. Safdar,
• Y. Zhang,
• L. Pusztai

Affiliations

N. Harbeck

J.-F. Boileau

S. Modi

C. Kelly

S. Ohno

J. Wu

A. Konpa

P. Herbolsheimer

S. Safdar

Y. Zhang

L. Pusztai